Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M109Revenue $M0Net Margin (%)0Z-Score58.0
Enterprise Value $M74.8EPS $-0.1Operating Margin %0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book3.110-y EBITDA Growth Rate %0Quick Ratio31.3Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio31.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-50.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-53.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M245ROI % (ttm)-111.7Gross Margin Increase y-yN

Gurus Latest Trades with ONCS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

ONCS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ONCS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MAIDA ANTHONY E IIIDirector 2014-03-20Buy22,800$0.81-45.68view
DHILLON PUNITPresident and CEO 2014-03-19Buy50,000$0.8-45view

Press Releases about ONCS :

    Quarterly/Annual Reports about ONCS:

    News about ONCS:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    ONCOSEC MEDICAL INC Financials Dec 13 2014
    10-Q for OncoSec Medical, Inc. Dec 10 2014
    ONCOSEC MEDICAL INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 10 2014
    OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse Dec 09 2014
    OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse Dec 09 2014
    ONCOSEC MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 08 2014
    OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015 Dec 08 2014
    OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015 Dec 08 2014
    OncoSec Reports Positive Top-Line Six-Month Primary Endpoint Data from Phase II Melanoma Trial of... Dec 05 2014
    OncoSec Reports Positive Top-Line Six-Month Primary Endpoint Data from Phase II Melanoma Trial of... Dec 05 2014
    OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014 Dec 05 2014
    OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014 Dec 05 2014
    OncoSec Reports ImmunoPulse May Prolong Survival Based on Analysis of Long-Term Survival Data from... Dec 04 2014
    PerkinElmer, UCLA and OncoSec Collaborate to Evaluate Patient-Selection Biomarker in Immunotherapy Dec 02 2014
    OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate... Dec 02 2014
    OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate... Dec 02 2014
    OncoSec Medical to Present at Two Events in December Nov 28 2014
    OncoSec Medical to Present at Two Events in December Nov 28 2014
    Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical Nov 26 2014
    Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical Nov 26 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK